|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
These findings show that TSP-1 is a transcriptional repression target of PRMT6 and suggest that neutralizing the activity of PRMT6 could inhibit tumor progression and therefore may be of cancer therapeutic significance.
|
19509293 |
2009 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
These findings show that TSP-1 is a transcriptional repression target of PRMT6 and suggest that neutralizing the activity of PRMT6 could inhibit tumor progression and therefore may be of cancer therapeutic significance.
|
19509293 |
2009 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
These findings show that TSP-1 is a transcriptional repression target of PRMT6 and suggest that neutralizing the activity of PRMT6 could inhibit tumor progression and therefore may be of cancer therapeutic significance.
|
19509293 |
2009 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.020 |
Biomarker
|
disease |
BEFREE |
Although the cellular role of PRMT6 is not well understood, it has been implicated in human immunodeficiency virus pathogenesis, DNA repair, and transcriptional regulation.
|
19509293 |
2009 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To identify in a nonbiased manner genes regulated by PRMT6 expression, we performed a microarray analysis on U2OS osteosarcoma cells transfected with control and PRMT6 small interfering RNAs.
|
19509293 |
2009 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
To identify in a nonbiased manner genes regulated by PRMT6 expression, we performed a microarray analysis on U2OS osteosarcoma cells transfected with control and PRMT6 small interfering RNAs.
|
19509293 |
2009 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To identify in a nonbiased manner genes regulated by PRMT6 expression, we performed a microarray analysis on U2OS osteosarcoma cells transfected with control and PRMT6 small interfering RNAs.
|
19509293 |
2009 |
|
Malformations of Cortical Development, Group II
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we show that PRMT6-deficient U2OS cells exhibited cell migration defects that were rescued by blocking the secreted TSP-1 with a neutralizing peptide or blocking alpha-TSP-1 antibody.
|
19509293 |
2009 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.
|
20473859 |
2011 |
|
Non-obstructive azoospermia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The combined analyses identified significant (P < 5.0 × 10(-8)) associations between NOA risk and common variants near PRMT6 (rs12097821 at 1p13.3: odds ratio (OR) = 1.25, P = 5.7 × 10(-10)), PEX10 (rs2477686 at 1p36.32: OR = 1.39, P = 5.7 × 10(-12)) and SOX5 (rs10842262 at 12p12.1: OR = 1.23, P = 2.3 × 10(-9)).
|
22197933 |
2011 |
|
Malignant Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Protein arginine methyltransferase-6 (PRMT6) regulates steroid-dependent transcription and alternative splicing and is implicated in endocrine system development and function, cell death, cell cycle, gene expression and cancer.
|
22673335 |
2012 |
|
Primary malignant neoplasm
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Protein arginine methyltransferase-6 (PRMT6) regulates steroid-dependent transcription and alternative splicing and is implicated in endocrine system development and function, cell death, cell cycle, gene expression and cancer.
|
22673335 |
2012 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that dysregulation of PRMT6-dependent transcription and alternative splicing may be involved in breast cancer pathophysiology and the molecular consequences identifying a unique and informative biomarker profile.
|
22673335 |
2012 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that dysregulation of PRMT6-dependent transcription and alternative splicing may be involved in breast cancer pathophysiology and the molecular consequences identifying a unique and informative biomarker profile.
|
22673335 |
2012 |
|
Mammary Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The PRMT6-dependent transcriptional and alternative splicing targets identified in vitro were validated in human breast tumours.
|
22673335 |
2012 |
|
Malignant Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
We conclude that PRMT6 acts as an oncogene in breast cancer cells, promoting growth and preventing senescence, making it an attractive target for cancer therapy.
|
22987071 |
2012 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
We conclude that PRMT6 acts as an oncogene in breast cancer cells, promoting growth and preventing senescence, making it an attractive target for cancer therapy.
|
22987071 |
2012 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
PRMT6 knock-down (KD) results in a p21 derepression in breast cancer cells, which is p53-independent, and leads to cell cycle arrest, cellular senescence and reduced growth in soft agar assays and in severe combined immunodeficiency (SCID) mice for all the cancer lines examined.
|
22987071 |
2012 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
PRMT6 knock-down (KD) results in a p21 derepression in breast cancer cells, which is p53-independent, and leads to cell cycle arrest, cellular senescence and reduced growth in soft agar assays and in severe combined immunodeficiency (SCID) mice for all the cancer lines examined.
|
22987071 |
2012 |
|
Severe Combined Immunodeficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PRMT6 knock-down (KD) results in a p21 derepression in breast cancer cells, which is p53-independent, and leads to cell cycle arrest, cellular senescence and reduced growth in soft agar assays and in severe combined immunodeficiency (SCID) mice for all the cancer lines examined.
|
22987071 |
2012 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we investigate the molecular mechanism by which protein arginine methyltransferase 6 (PRMT6) exerts anti-invasiveness effect against breast cancer cells and prostate cancer cells.
|
23380452 |
2013 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we investigate the molecular mechanism by which protein arginine methyltransferase 6 (PRMT6) exerts anti-invasiveness effect against breast cancer cells and prostate cancer cells.
|
23380452 |
2013 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, this suppression of migration and invasion by PRMT6 overexpression was significantly rescued by specific knock-down of TSP-1.
|
23380452 |
2013 |